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i n t rodUC t i on
background
With estimates of the population-based incidence of between 
48 and 134 per 100,000 adults per year, acute upper 
gastro intestinal bleeding can be considered a common 
reason to visit emergency departments (ED).1-4 Reported 
mortality rates for such patients range from 5% to 14% in 
different studies.3-7 The presentation of patients with upper 
gastro intestinal bleeding varies from clinically insignificant 
bleeding to hypovolaemic shock. Depending on the nature of 
the bleeding, some of these patients do not need immediate 
treatment because the bleeding will stop spontaneously 
with little risk of clinical complications or rebleeding. These 
patients could be further treated as outpatients. However, 
because the cause of the bleeding cannot be determined 
from the clinical presentation and emergency endoscopy is 
not readily available in the ED, it is common practice to admit 
patients for observation and endoscopy. 
Clinical characteristics and the cause of the bleeding as 
diagnosed with endoscopy are highly predictive of adverse 
outcomes such as rebleeding and mortality.8 Quantification 
of clinical severity with a dedicated score could be a useful 
tool toward a more objective determination of the need 
for immediate intervention. Several scoring systems 
have been developed to stratify patients with acute upper 
gastrointestinal bleeding according to prognosis.9-12 The 
Rockall score is such a risk stratification tool that is based 
on clinical and endoscopic findings.12
In 2000 the Glasgow Blatchford bleeding Scale (GBS) 
was developed. The GBS is a screening tool to assess the 
likelihood that a patient with acute upper gastro intestinal 
bleeding will need medical intervention (e.g. blood 
transfusion, endoscopic or surgical treatment) only based 
on patient history, clinical examination and laboratory 
tests. Advantages of the GBS include absence of highly 
subjective variables (e.g. severity of systemic diseases) and 
the fact that there is no need for endoscopy.9
The Haemoglobin-Urea-Pulse-Systolic blood pressure 
(HUPS) score is a simplified fast-track risk screening tool 
that only uses the clinical and laboratory data of the GBS.8 
According to the original article it should only be used 
when patients have no major comorbidity. GBS and HUPS 
scores are unique because they can easily be determined 
in the ED. 
Several studies have shown that the GBS score can 
identify patients who can be safely sent home without any 
endoscopic intervention.12-14 In the initial study, patients 
with a GBS score of 0 were classified as low risk for the 
need of clinical intervention. Later studies showed that a 
cut-off value of 2 still reliably identified patients with no 
need for immediate intervention.1,9,10,13-15 The GBS has not 
yet been evaluated for use in the Netherlands. The aim 
of the present study was to validate the GBS scale in the 
Netherlands and to determine the cut-off value for safely 
treating patients as outpatients. A further aim was to 
compare the GBS scale system with the HUPS score and 
the Rockall score as to their ability to predict absence of the 
need for immediate treatment.
Mat e r i a l s  a n d  M e t Hods
study design and setting
This historical cohort study was performed in the 
Maastricht University Medical Centre (MUMC). Each year 
about 22,750 patients visit the ED of whom 5075 patients 
present to internal medicine or gastroenterology. About 
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200 of these patients are investigated under the diagnosis 
of acute upper gastrointestinal bleeding. Endoscopy, 
mainly performed in the endoscopy department, was 
available 24 hours a day, seven days a week. The study 
was conducted with the approval of the medical ethical 
committee of MUMC.
study population
We retrospectively reviewed the charts of all patients 
admitted to the ED for suspected acute upper 
gastro intestinal bleeding in the following period: 1 July 
2009 and 31 January 2010. Patients had to fulfil all of 
the following inclusion criteria: 1) presentation at ED 
with haematemesis, melaena, tarry stool or syncope 
with anaemia; 2) diagnosis of acute upper gastroin-
testinal bleeding was included in the working differential 
diagnosis formulated by the internist or gastroenterologist; 
and 3) age over 18 years. Patients with signs of chronic 
bleeding (microcytic anaemia) were excluded. In contrast 
to other studies we did not include patients who developed 
acute upper gastrointestinal bleeding while hospitalised 
for other reasons.
data collection/methods of measurement
Data were collected using the ED files and the electronic 
database of the hospital. To check completeness of obtained 
data, the reports of all gastroduodenal endoscopies 
performed in the research period were screened as well. 
The abstraction of the charts was performed by a research 
student, who was not blinded for the study hypothesis. All 
patients were discussed with a gastroenterologist (YK).
The following data were collected: date of admission 
to the ED, symptoms and signs of the gastrointestinal 
bleeding, haemodynamic variables (pulse and systolic 
blood pressure), laboratory results (serum haemoglobin 
and urea concentrations), demographic information, 
current medication, comorbidity, length of in-hospital 
stay, moment (inpatient or outpatient) and findings of 
endoscopy. 
As comorbidities we recorded hepatic disease/failure, 
kidney disease/failure, cardiac failure, and disseminated 
malignancy. Used medication was retrieved from 
the ED chart with special attention for the following 
medication: proton pump inhibitors, carbasalate 
calcium, anticoagulants, H2 antagonists, non-steroidal 
anti-inflammatory medication or corticosteroids. If items 
were not mentioned in either the ED chart or the electronic 
database we considered them to be negative. 
We calculated the Glasgow Blatchford (table 1), HUPS and 
Rockall scores of the patients based on the collected data.
Need for treatment during the period of 28 days following 
presentation was considered to be present when, in 
this period, treatment (e.g. blood transfusion, surgical, 
radiological or endoscopic intervention) was actually 
performed, when rebleeding requiring readmission 
occurred, or when the patient died. Information about 
readmission, rebleeding or death was gathered from the 
charts and/or general practitioner. 
data processing and sensitivity analysis
Statistical analysis was performed using SPSS 15.0. 
Data are presented as means with standard deviation 
(SD) and proportions where appropriate with exact 95% 
confidence intervals (CI). We calculated areas under the 
receiver-operating curves with 95% CI as estimates of the 
discriminatory ability of the scoring tool. Sensitivity and 
specificity of dichotomised scores at usual cut-off levels 
were calculated to guide the choice for a proper cut-off 
level. Likelihood ratios for individual scores were calculated 
to estimate the diagnostic information associated with each 
score. We refrained from statistical testing because of the 
exploratory nature of the study.
r e sU lt s
Characteristics and management of patients with acute 
upper gastrointestinal bleeding
A total of 103 patients with acute upper gastrointestinal 
bleeding were enrolled in this study. Table 2 outlines 
the demographic characteristics and outcomes for these 
patients. Eighty-one (79%) underwent endoscopy. A total 
of 11 patients (10.7%) suffered from rebleeding in the 
table 1. The Glasgow Blatchford bleeding scale
admission risk markers score value
Serum urea (mmol/l)
6.5 - 7.9 2
8.0 - 9.9 3
10.0 - 24.9 4
>24.9 6
Haemoglobulin for men (mmol/l)
7.5 - 8.1 1
6.2 - 7.4 3
<6.2 6
Haemoglobulin for women (mmol/l)
6.2 - 7.5 1
<6.2 6
Systolic blood pressure (mmHg)
100 - 109 1
90 - 99 2
<90 3
Other markers
Pulse ≥ 100/min 1
Presentation with melaena 1
Presentation with syncope 2
Hepatic disease 2
Cardiac failure 2
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follow-up period; also 11 patients (10.7%) died during the 
follow-up period. 
Table 3 shows the endoscopic findings of these patients. For 
11 patients (11%) it was not possible to calculate the GBS 
and HUPS scores because some of the haemodynamic 
or laboratory variables were missing. In 24 patients 
(23%) the Rockall score could not be calculated because 
endoscopy had not been performed. Table 4 shows the 
likelihood ratios for the different values of the GBS in 
the validation group of the original study population 
(Blatchford validation group) and in our patient group. 
Receiver-operating characteristic analysis showed very 
good discriminative ability with an area under the curve 
(AUC) of 0.94 (95% CI 0.90 - 0.98) (figure 1). 
Four patients (4%) had a GBS score of 0, while 17 (18%) 
of patients had a score below 2. In the 28-day follow-up 
period, none of these patients needed treatment. For a 
cut-off value of 0, sensitivity and specificity for the need of 
treatment were 100% (95% CI 95 to 100%) and 12% (95% 
CI 4 to 26%) respectively. With a cut-off value of 2 the 
sensitivity was still 100% (95% CI 95 to 100%), while the 
specificity increased to 51% (95% CI 35 to 67%).
Comparison of the three different risk scoring systems
Using the cut-off value of ≤2 points as suggested in the 
original study, the Rockall score classified 21 patients 
(26.6%) at low risk of needing treatment (figure 2). 
However, of these 21, four patients met the study definition 
of needing clinical intervention: three patients received 
blood transfusion and one patient needed an endoscopic 
table 2. Characteristics and management of the study 
population
Characteristics of patients total of patients 
(n=103)
Sex, n. (%) Men 51 (49.5)
Age (years), mean (SD) 65.7 (18.2)
Medication,  
n. (%)
Proton pump inhibitors 26 (25.2)
Carbasalate calcium 27 (26.2)
Non-steroidal anti- 
inflammatory drugs
11 (10.7)
Corticosteroids 5 (4.9)
Vitamin K antagonists 24 (23.7)
Clopidogrel 7 (6.9)
Low-molecular-weight 
heparin
2 (2.0)
H2 Blockers 4 (3.9)
Comorbidity, 
n. (%)
Cardiac failure 19 (18.4)
Cardiac ischaemia 22 (21.4)
Renal disease 9 (8.7)
Hepatic disease 15 (14.6%)
Disseminated malignancy 9 (8.7%)
Management
Admission,  
n. (%)
Yes 85 (82.5)
Hospital stay (days), median (range) 4.0 (1-50)
Endoscopy Inpatient 68 (60.0)
Outpatient 13 (12.6)
Time to endoscopy (hours), mean (SD) 17:22 (26:08)
Time between admission and endoscopy 
(hours), mean (SD)
14:08 (27:42)
Rebleeding, n (%) 11 (10.7)
Mortality, n (%) 11 (10.7)
table 3. Endoscopic findings*
no need for 
intervention 
(n=27)
need for 
intervention 
(n=54)
Normal, n. (%) 16 (61.5) 17 (30.9)
Oesophagitis, n. (%) 5 (19.2) 8 (14.5)
Gastric ulcer, n. (%) 4 (15.4) 8 (14.5)
Mallory-Weiss tear, n. (%) 4 (15.4) 1 (1.8)
Duodenal ulcer, n. (%) 1 (2.7) 6 (10.9)
Varices, n. (%) 0 12 (22.2)
Malignancy, n. (%) 0 3 (5.5)
Angiodysplastic lesion, n. (%) 0 3 (5.5)
Bulbitis/duodenitis, n. (%) 0 2 (3.7)
Watermelon stomach, n. (%) 0 1 (1.8)
Dieulafoye lesion, n. (%) 0 1 (1.8)
Portal gastropathy, n. (%) 0 1 (1.8)
Other, n. (%) 0 1 (1.8)
*some patients had more than one endoscopic finding.
table 4. Validation of the GBS score
risk 
score
blatchford validation group 
(n=197)5
our validation group (n=92)
total of 
patients, 
n.
inter-
vention 
needed, n 
(%)
lr total of 
patients, 
n. 
inter-
vention 
needed, n. 
(%)
lr
0 36 1    (2.8) 0.03 4 0 0.00
1 32 3    (9.4) 0.13 9 0 0.00
2 12 1    (8.3) 0.11 4 0 0.00
3 13 3    (23.1) 0.36 4 1    (25.0) 0.19
4 9 4    (44.4) 0.97 5 2    (20.0) 0.37
5 11 4    (36.4) 0.69 4 2    (50.0) 0.56
6 14 11  (78.6) 4.45 1 1    (100.0) ∞
7 13 10  (76.9) 4.04 8 5    (62.5) 0.93
8 13 10  (76.9) 4.04 8 4    (50.0) 0.56
9 4 4    
(100.0)
∞ 4 4    (100.0) ∞
10 6 5    (83.3) 6.07 7 6    (85.7) 3.36
11 13 12  (92.3) 14.56 7 7    (100.0) ∞
12 9 9    
(100.0)
∞ 8 8    (100.0) ∞
13 6 6    
(100.0)
∞ 5 5    (100.0) ∞
≥14 6 6    
(100.0)
∞ 14 14  (100.0) ∞
Total 197 89  (45.2) 92 59 (64.1)
lr = likelihood ratio.
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intervention. The HUPS score identified 14 patients 
(15.2%) with score 0. None of these patients needed 
intervention (figure 2). We compared the ROC curves of 
the three scoring systems for the patient group in which all 
three scores could be calculated. With an AUC of 0.94 (CI 
0.89 to 0.99), the GBS proved to be superior to the HUPS 
score and the complete Rockall score with AUCs of 0.85 (CI 
0.75 to 0.95) and 0.88 (CI 0.79 to 0.96)
d i s CUs s i on
In this study we validated the Glasgow Blatchford bleeding 
scale in the setting of a Dutch university hospital. The GBS 
showed to have good discriminative ability to distinguish 
acute upper gastrointestinal bleeding patients who do and 
who do not need intervention in the ED. The area under the 
ROC curve was 0.94 (95% CI 0.90 - 0.98) which is similar 
to the AUC in the original validation group of Blatchford 
et al.: 0.92 (95% CI 0.88 to 0.95). Diagnostic information 
per individual GBS expressed as likelihood ratios showed 
roughly the same trend in the original validation group and 
in our study. However, it is evident that a much larger study 
will be needed to reliably estimate the likelihood ratios and 
make valid comparisons between groups.
The cut-off value between low or high risk of needing 
treatment was set at 0 in the original study.9 In this way 
a sensitivity of 98.9% was reached. In our group, 4% of 
patients had a score of zero with a sensitivity of 100%. 
Previous studies found a higher percentage of patients with 
a score of 0, ranging from 8 to 17%.15-17 Stanley et al. used 
the cut-off value of 0 and identified 123 patients (22%) as 
low risk and managed 84 (17%) of them as outpatients.15
In our study a higher cut-off value of 2 still had a 
sensitivity of 100%. Therefore, the 18% of the patients with 
this score could have been safely managed as outpatients. 
Previous studies also indicated that a cut-off value of 2 
should be safe. Stephens et al. used the combination GBS 
<2 and age younger than 70 years as a criterion, because 
they believed that it was not safe to treat the elderly as 
figure 1. ROC curves of the three different scoring systems
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outpatients. They found that this way 10% of their patients 
with acute upper gastrointestinal bleeding could be safely 
managed without hospital admittance.17 Srirajaskanthan et 
al. identified 64 patients (38.6%) who had a GBS score of 
<2, all of whom could be safely managed as outpatients.1 
The Rockall score was originally developed to predict the 
risk of death and rebleeding.12 To prevent such events it is 
clear that one should be able to identify those patients who 
need treatment. Therefore, in practical terms the Rockall 
score has the same purpose as the other two scoring 
instruments. Until now the HUPS score has not been 
externally validated. 
Our study shows that in our population, the discriminative 
ability of the GBS score was superior to the complete Rockall 
score and the HUPS score. Earlier reports also indicated that 
the GBS is better than the complete Rockall score.9,10,15,16 The 
inferior performance of the HUPS score can possibly be 
attributed to the fact that it is only considered to be useful in 
the absence of other major pathology.
There were several differences between our study and 
earlier studies in this field. Unlike other studies we did 
not exclude patients with bleeding varicose veins and 
patients without endoscopy in the follow-up. We did that 
because the purpose of the risk scoring tools is to support 
clinical decision making in the absence of endoscopic 
findings. We did not include patients who developed acute 
upper gastrointestinal bleeding while admitted to the 
hospital because they are not seen in the ED and are not 
representative of the acute upper gastrointestinal bleeding 
patients who come to the ED. Also, we used the 28-day 
mortality and rebleeding and not only in-hospital events 
because we also included patients who were primarily 
treated as outpatients.
A limitation of our study is the use of retrospective data 
collection from hospital files. We were therefore dependent 
on the completeness of the medical chart. It is possible 
that we missed some relevant information. For 11% of the 
patients we were not able to collect all the data that were 
needed to calculate the GBS and HUPS scores. However, 
the main limitation of the study is its small size. Before 
introduction of the GBS score for clinical purposes the 
study should be repeated in a much larger population and 
preferably with prospective data collection.
The GBS and HUPS scoring systems are unique because 
they do not require endoscopy, and therefore they can 
easily be used at the ED. With a cut-off value of 2, an 
appreciable number of patients can be identified for whom 
treatment as outpatients is preferable. This would result in 
a reduction of hospital days, more adequate and efficient 
patient care and lower healthcare costs. It is reassuring 
that, despite differences in the composition of patient 
populations, the GBS seems to perform equally well in the 
Netherlands as in its original validation study and other 
studies.
In conclusion, the GBS score appears to be a good predictor of 
the need for treatment in a Dutch ED population of patients 
with acute upper gastrointestinal bleeding. It was superior 
to the often used complete Rockall and HUPS scores. Larger 
studies are needed to substantiate the conclusions.
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